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Letter by Cingolani et al Regarding Article, 
“Ventricular Phosphodiesterase-5 Expression Is 
Increased in Patients With Advanced Heart 
Failure and Contributes to Adverse Ventricular 
Remodeling After Myocardial Infarction in Mice” 
To the Editor:
Pokreisz et al1 recently published an interesting article in which 
they show increased cardiac left ventricular phosphodiesterase-5A 
(PDE5A) expression in patients with heart failure. They also gener­
ated a PDE5A transgenic mouse in which overexpression of this 
cGMP-selective phosphodiesterase worsened ventricular remodeling 
and function after myocardial infarction. Therefore, the obvious 
conclusion seems to be that inhibition of PDE5A might protect 
against postmyocardial infarction remodeling. Although the authors 
show cGMP to be related to these cardiac architectural changes, they 
raise new questions about the possible cGMP downstream signaling 
mechanisms involved. For the reasons outlined below, we believe a 
possible pathway that might explain the findings by Pokreisz et al is 
the one involving cGMP-protein kinase G (PKG)-Na' /H' Exchanger 
(NHE-1) inhibition:
1. After coronary artery ligation, PDE5A inhibition by Sildenafil 
ameliorated postinfarction remodeling in rats.2 This effect was 
evident without differences in infarct size between treated and 
untreated animals (such as in the article by Pokreisz et al) and was 
accompanied by an increase in PKG activity. In the same article, 
PDE5A inhibition by Sildenafil as well as by EmD360527/5 reduced 
NHE-1 activity whereas inhibition of PkG-1 activity by KT5823 
restored NHE-1 normal function in Sildenafil-treated cardiac papil­
lary muscles.2
2. Pokreisz et al, as well as others, reported that PDE5A localized 
mainly to the intercalated disks. NHE-1 also colocalizes to this 
site.3,4
3. It seems that neither inhibition nor overexpression of PDE5A 
influences cardiac function or remodeling under basal conditions. 
Interestingly, that also seems to be the case for the NHE-1. In another 
article published in Circulation,5 inhibition of p90RSK, a kinase that 
phosphorylates and activates NHE-1, protected against ischemia/ 
reperfusion and inhibited NHE-1 activity only after myocytes were 
exposed to an acidic load (as it usually occurs after myocardial 
infarction) but not under basal conditions. Inhibition of PDE5A also 
decreases NHE-1 activity only after cells are being challenged with 
an acidic load and not under basal conditions.2
4. Sildenafil has been shown to inhibit extracellular signal- 
regulated kinase (ERK) 1/2,6 which phosphorylates p90RSK and 
activates NHE-1.7
In conclusion, we believe enough scientific evidence exists to 
consider NHE-1 as a possible downstream mediator in PDE5A 
inhibition-induced amelioration of ventricular remodeling, particu­
larly in situations where the myocardium is exposed to acidic loading 
states, such as in the setting of acute myocardial infarction. Studies 
further exploring this intriguing pathway are warranted.
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